[go: up one dir, main page]

ES8705521A1 - Un metodo de producir un polipetido similar a factor de necrosis de tumores (tnf) de mamiferos. - Google Patents

Un metodo de producir un polipetido similar a factor de necrosis de tumores (tnf) de mamiferos.

Info

Publication number
ES8705521A1
ES8705521A1 ES550260A ES550260A ES8705521A1 ES 8705521 A1 ES8705521 A1 ES 8705521A1 ES 550260 A ES550260 A ES 550260A ES 550260 A ES550260 A ES 550260A ES 8705521 A1 ES8705521 A1 ES 8705521A1
Authority
ES
Spain
Prior art keywords
dna
tnf
mammals
producing
necrosis factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES550260A
Other languages
English (en)
Other versions
ES550260A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Original Assignee
Biogen NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen NV filed Critical Biogen NV
Publication of ES550260A0 publication Critical patent/ES550260A0/es
Publication of ES8705521A1 publication Critical patent/ES8705521A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

METODO DE PRODUCIR UN POLIPEPTIDO SIMILAR A FACTOR DE NECROSIS DE TUMORES (TNF) DE MAMIFEROS. CONSISTE EN CULTIVAR UN HOSPEDANTE PROCARIOTICO TRANSFORMADO CON UNA MOLECULA DE ADN RECOMBINANTE SELECCIONADA DE: A) LA INSERCION DE ADN DE P-MTNF-3; B) LA INSERCION DE ADN DE P-HTNF-1; C) SECUENCIAS DE ADN QUE SE HIBRIDAN A UNA O AMBAS DE LAS INSERCIONES DE ADN A) Y B); Y D) SECUENCIAS DE ADN QUE CODIFICAN POR EXPRESION UN POLIPEPTIDO CODIFICADO POR EXPRESION POR CUALQUIERA DE LAS INSERCIONES Y SECUENCIAS DE ADN QUE ANTECEDEN, ESTANDO ESTAS SECUENCIAS DE ADN ENLAZADAS OPERATIVAMENTE A UNA SECUENCIA DE CONTROL DE EXPRESION SELECCIONADA DE T4 Y PL-T4. TIENE UTILIDAD FARMACEUTICA POR SU ACTIVIDAD CITOTOXICA.
ES550260A 1984-12-21 1985-12-20 Un metodo de producir un polipetido similar a factor de necrosis de tumores (tnf) de mamiferos. Expired ES8705521A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68459584A 1984-12-21 1984-12-21
US78584785A 1985-10-09 1985-10-09

Publications (2)

Publication Number Publication Date
ES550260A0 ES550260A0 (es) 1987-05-01
ES8705521A1 true ES8705521A1 (es) 1987-05-01

Family

ID=27103367

Family Applications (1)

Application Number Title Priority Date Filing Date
ES550260A Expired ES8705521A1 (es) 1984-12-21 1985-12-20 Un metodo de producir un polipetido similar a factor de necrosis de tumores (tnf) de mamiferos.

Country Status (16)

Country Link
US (1) US5487984A (es)
EP (3) EP0216786B1 (es)
JP (4) JP2557053B2 (es)
KR (1) KR940010865B1 (es)
AT (1) ATE73856T1 (es)
AU (2) AU601675B2 (es)
DE (1) DE3585690D1 (es)
DK (1) DK399786A (es)
ES (1) ES8705521A1 (es)
FI (1) FI86194C (es)
HU (1) HUT40702A (es)
IE (1) IE58709B1 (es)
NO (1) NO855216L (es)
NZ (1) NZ214711A (es)
PT (1) PT81754B (es)
WO (1) WO1986003751A2 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288852A (en) * 1984-03-06 1994-02-22 Dainippon Pharmaceutical Co., Ltd. Human tumor necrosis factor polypeptides
JPS6248634A (ja) * 1985-07-23 1987-03-03 Mochida Pharmaceut Co Ltd 新規アミノ酸組成物、その製造方法及び該アミノ酸組成物を含有する医療組成物
US5059530A (en) * 1985-09-30 1991-10-22 Suntory Ltd. Expression vector for human TNF
JPH0698004B2 (ja) * 1985-09-30 1994-12-07 サントリー株式会社 Ｔｎｆ発現用新規プラスミド
US4894439A (en) * 1986-05-22 1990-01-16 Cetus Corporation N-terminal derivatives of tumor necrosis factor purified by microporous PTFE membranes
US4677197A (en) * 1985-10-30 1987-06-30 Cetus Corporation Purification method for tumor necrosis factor
NZ219027A (en) * 1986-01-24 1989-09-27 Genentech Inc Antiviral composition containing interferon tumour necrosis factor and/or lymphotoxin
CA1340998C (en) * 1986-02-04 2000-05-23 Den'ichi Mizuno Dnas and processes for their preparation, novel plasmids possessing them, novel polypeptides and processes for their preparation and novel anti-tumor agents comprising said polypeptides
US4894225A (en) * 1987-03-02 1990-01-16 Cetus Corporation Combination therapy using antitumor immunotoxins with tumor necrosis factor
GB2217325B (en) * 1988-04-08 1991-11-20 British Bio Technology Synthetic gene for tumour necrosis factor alpha.
CA2067821A1 (en) * 1989-10-24 1991-04-25 Cetus Oncology Corporation Infective drug delivery system using recombinant retroviral vectors
US6420374B1 (en) 1990-11-30 2002-07-16 Fred Hutchinson Cancer Research Center Use of xanthines as immunosuppressants and to inhibit allograft reactions
US5891704A (en) * 1992-11-19 1999-04-06 Anticancer, Inc. Method to produce high levels of methioninase
DE69332357T2 (de) * 1992-11-19 2003-06-18 Anticancer Inc., San Diego Verwendung von methioninase als antitumormittel in der antimethionin-chemotherapie
US5715835A (en) * 1992-11-19 1998-02-10 Anticancer, Inc. Methods for treating and reducing the potential for cardiovascular disease using methioninase compositions
US6461851B1 (en) 1992-11-19 2002-10-08 Anticancer, Inc. High expression modules containing two or more tandem copies of a methioninase encoding sequence
US5888814A (en) * 1994-06-06 1999-03-30 Chiron Corporation Recombinant host cells encoding TNF proteins
AU3818095A (en) * 1994-10-20 1996-05-15 Industrial Research Limited Separation of amino acids and peptides from protein hydrolysates
US7217788B2 (en) * 1996-03-14 2007-05-15 Human Genome Sciences, Inc. Human tumor necrosis factor delta polypeptides
AU2003236393B2 (en) * 1996-03-14 2006-02-02 Human Genome Sciences, Inc. Methods of Treating or Preventing Inflammation or Rheumatoid Arthritis
AU761216B2 (en) * 1996-03-14 2003-05-29 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
US6509170B1 (en) 1996-03-14 2003-01-21 Human Genome Sciences, Inc. Polynucleotides encoding human tumor necrosis factor delta
ATE254135T1 (de) * 1996-03-14 2003-11-15 Human Genome Sciences Inc Humaner tumornekrosefaktor delta und epsilon
US6541224B2 (en) 1996-03-14 2003-04-01 Human Genome Sciences, Inc. Tumor necrosis factor delta polypeptides
US6617171B2 (en) * 1998-02-27 2003-09-09 The General Hospital Corporation Methods for diagnosing and treating autoimmune disease
US6395273B1 (en) * 1998-06-10 2002-05-28 Promega Corporation Prevention and treatment of inflammatory bowel disease
US6599710B1 (en) 1999-03-10 2003-07-29 The General Hospital Corporation Treatment of autoimmune disease
CA2446734A1 (en) * 2001-05-24 2002-11-28 Human Genome Sciences, Inc. Antibodies against tumor necrosis factor delta (april)
US7582313B2 (en) * 2002-06-27 2009-09-01 The General Hospital Corporation Methods of organ regeneration using Hox 11-expressing pluripotent cells
US7628988B2 (en) 2002-06-27 2009-12-08 The General Hospital Corporation Methods and compositions for treating type 1 diabetes
AU2003290948A1 (en) * 2002-11-15 2004-06-15 The General Hospital Corporation Screening methods to identify treatments for autoimmune disease
CA2508375C (en) * 2002-12-02 2014-05-27 Abgenix, Inc. Antibodies directed to tumor necrosis factor and uses thereof
JP2005132795A (ja) * 2003-10-31 2005-05-26 Genichiro Soma 抗悪性神経膠腫剤及び動物用抗悪性神経膠腫剤
US20080102054A1 (en) * 2005-01-18 2008-05-01 Faustman Denise L Compositions Containing Agm Cells And Methods Of Use Thereof
ES2885423T3 (es) 2013-02-07 2021-12-13 Massachusetts Gen Hospital Procedimientos para la expansión o el empobrecimiento de células T reguladoras
KR102393711B1 (ko) 2013-10-17 2022-05-04 더 제너럴 하스피탈 코포레이션 자가면역 질환의 치료에 반응하는 대상체의 식별 방법 및 그의 치료를 위한 조성물
US11111284B2 (en) * 2014-08-21 2021-09-07 The General Hospital Corporation Tumor necrosis factor superfamily and TNF-like ligand muteins and methods of preparing
CN107849142B (zh) 2015-05-15 2022-04-26 综合医院公司 拮抗性抗肿瘤坏死因子受体超家族抗体
US20190135929A1 (en) 2015-08-28 2019-05-09 The General Hospital Corporation Agonistic anti-tumor necrosis factor receptor 2 antibodies
WO2017059132A1 (en) 2015-09-29 2017-04-06 The General Hospital Corporation Methods of treating and diagnosing disease using biomarkers for bcg therapy
EP3455262A4 (en) 2016-05-13 2020-04-08 The General Hospital Corporation ANTAGONIST ANTIBODIES OF THE NECROSIS FACTOR RECEPTOR SUPERFAMILY AGAINST TUMORS
CN111747931A (zh) * 2019-03-29 2020-10-09 深圳福沃药业有限公司 用于治疗癌症的氮杂芳环酰胺衍生物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4332892A (en) 1979-01-15 1982-06-01 President And Fellows Of Harvard College Protein synthesis
NL7903195A (nl) 1979-04-24 1980-10-28 Philips Nv Inrichting voor kunstmatige nagalm.
US4425437A (en) 1979-11-05 1984-01-10 Genentech, Inc. Microbial polypeptide expression vehicle
US4309418A (en) * 1980-03-25 1982-01-05 Sloan-Kettering Research Institute For Cancer Anti-tumor agent from human serum and process
US4338397A (en) 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
DK171301B1 (da) 1980-06-06 1996-08-26 Biogen Inc Plasmid-vektorer, fremgangsmåde til fremstilling deraf samt fremgangsmåde til fremstilling af polypeptid
FR2513124B1 (fr) * 1981-07-21 1989-11-17 Hayashibara Biochem Lab Production et applications du facteur de lyse des cellules-cibles
AU8956582A (en) * 1982-10-06 1984-04-24 Makitsubo, T. Process for extracting tumor necrosis factor from macrophage
CA1265444A (en) * 1983-06-27 1990-02-06 Lloyd J. Old Effect of human tumor necrosis factor and human interferon on human cancer cells and methods
JPH0695939B2 (ja) * 1983-12-02 1994-11-30 大日本製薬株式会社 ウサギ癌壊死因子をコ−ドするクロ−ン化ｄνａ
EP0148311B1 (en) * 1983-12-26 1988-07-20 Asahi Kasei Kogyo Kabushiki Kaisha A novel physiologically active polypeptide
JPS60185799A (ja) * 1984-03-06 1985-09-21 Dainippon Pharmaceut Co Ltd ヒト癌壊死因子
DE19975063I2 (de) * 1984-03-06 2005-08-18 Dainippon Pharmaceutical Co DNS den menschlichen Tumornekrosisfaktor kodierendund das menschliche Tumornekronisfaktor-Polypepti d.
US4879226A (en) * 1984-04-06 1989-11-07 Asahi Kasei Kogyo Kabushiki Kaisha Novel human physiologically active polypeptide
IL75318A (en) * 1984-05-31 1994-08-26 Genentech Inc Recombinant human memotoxin and methods for its recombinant production
DE3423234A1 (de) * 1984-06-23 1986-02-06 Boehringer Ingelheim International GmbH, 6507 Ingelheim Synergistische mischungen von interferonen und tumor-nekrose-faktor
GR851626B (es) * 1984-07-05 1985-11-26 Genentech Inc
US4677064A (en) * 1984-11-09 1987-06-30 Cetus Corporation Human tumor necrosis factor
JPS61124392A (ja) * 1984-11-22 1986-06-12 Asahi Chem Ind Co Ltd 遺伝子組換体の産生する生理活性物質の精製法
US4677663A (en) * 1985-07-05 1987-06-30 Melita Electronic Labs, Inc. Telephone answering and call forwarding improvement
JPH0698004B2 (ja) * 1985-09-30 1994-12-07 サントリー株式会社 Ｔｎｆ発現用新規プラスミド
US5182196A (en) * 1985-10-09 1993-01-26 Biogen, Inc. Expression systems for overproduction of desired proteins

Also Published As

Publication number Publication date
HUT40702A (en) 1987-01-28
ES550260A0 (es) 1987-05-01
AU5510490A (en) 1990-10-25
JP2548527B2 (ja) 1996-10-30
FI855130A0 (fi) 1985-12-20
DK399786D0 (da) 1986-08-21
JPH07213292A (ja) 1995-08-15
FI86194C (fi) 1992-07-27
FI86194B (fi) 1992-04-15
EP0313104A3 (en) 1989-07-12
JP2548526B2 (ja) 1996-10-30
DK399786A (da) 1986-08-21
KR940010865B1 (ko) 1994-11-18
JP2548525B2 (ja) 1996-10-30
ATE73856T1 (de) 1992-04-15
FI855130A7 (fi) 1986-06-22
JP2557053B2 (ja) 1996-11-27
NO855216L (no) 1986-06-23
IE853273L (en) 1986-06-21
JPS62501470A (ja) 1987-06-18
JPH07213293A (ja) 1995-08-15
WO1986003751A3 (en) 1986-08-14
KR860005023A (ko) 1986-07-16
IE58709B1 (en) 1993-11-03
NZ214711A (en) 1991-11-26
AU601675B2 (en) 1990-09-20
PT81754A (en) 1986-01-02
EP0216786A1 (en) 1987-04-08
AU5301486A (en) 1986-07-22
DE3585690D1 (de) 1992-04-23
JPH07213291A (ja) 1995-08-15
PT81754B (pt) 1987-12-30
EP0368367A1 (en) 1990-05-16
WO1986003751A2 (en) 1986-07-03
EP0313104A2 (en) 1989-04-26
EP0216786B1 (en) 1992-03-18
US5487984A (en) 1996-01-30

Similar Documents

Publication Publication Date Title
ES8705521A1 (es) Un metodo de producir un polipetido similar a factor de necrosis de tumores (tnf) de mamiferos.
ES2153037T3 (es) Lacasas purificadas de scytalidium y acidos nucleicos que las codifican.
ES2073571T3 (es) Aplicacion de nuevos fragmentos de adn como secuencia que codifica un peptido señal para la secrecion de proteinas maduras, mediante levaduras recombinantes, cassettes de expresion, levaduras transformadas y procedimiento correspondiente de preparacion de proteinas.
IT1206311B (it) Agente terapeutico a base di oligonucleotide e metodi per laproduzione dello stesso.
ES487106A0 (es) Un metodo para producir al menos un polipeptido que muestra antigenicidad de hbv
NO930011D0 (no) Tilfeldig boi-oligomer bibilotek og fremgangsmaate for syntese og anvendelse derav
HUT46061A (en) Dna sequences encoding hirudin-like protein and process for producing such proteins
ATE414775T1 (de) Polypeptide mit prolyldipeptidylaminopeptidase- aktivität und dafür kodierende nukleinsäuren
DK346385A (da) Genetiske sekvenser, hermed kodede interferon-peptider af type i og organismer, der producerer disse
ES547436A0 (es) Un procedimiento para producir un adn complementario clonadoo su adn modificado que codifica un polipeptido de factor denecrosis de tumores
DE3683447D1 (de) Verfahren zur herstellung von humanlysozym.
MX9203138A (es) Dominio de enlace cd2-de antigeno 3 (lfa-3) asociado con funcion linfositos.
DK295188D0 (da) Fibronectinbindende protein og fremgangsmaade til fremstilling heraf
ES474850A1 (es) Mejoras introducidas en un procedimiento para la sintesis depolinucleotidos
NL960017I1 (nl) Expressie van Factor VIII-activiteit in zoogdiercellen.
FI863626A7 (fi) DNA-sekvenssejä, yhdistelmä-DNA -molekyylejä ja menetelmiä ihmisen lip okortiinin kaltaisia polypeptidejä.
FI896261A7 (fi) Menetelmä proteiinin tai polypeptidin valmistamiseksi, polypeptidiä ko odaava DNA-sekvenssi, DNA-sekvenssin sisältämä mikro-organismi sekä po lypeptidi ja sen käyttö farmaseuttisena valmisteena
DK38889A (da) Onkogen-indkodet polypeptid med vaekstfaktoraktivitet
FI850814A7 (fi) Proteiineja, farmaseuttisia seoksia, geenejä, vektoreita, isäntäorgan ismeja ja menetelmiä niiden tuottamiseksi.
ES8205429A1 (es) Procedimiento para la preparacion de un plasmido que codifica para la secuencia de aminoacidos del interferon de fibro- blastos humanos.
CO4480058A1 (es) Genes codificantes y procedimiento de expresion de una nueva enzima: ftalil amidasa
ES2052513T3 (es) Nuevos polipeptidos, su fabricacion y empleo.
ES2091223T3 (es) Nuevas secuencias de adn que codifican polipeptidos semejantes a ancrod y composiciones que comprenden los productos de expresion de las mismas.
SE8502430D0 (sv) A cdna molecule coding for the expression of an interferon alfa type polypeptide, a bacterial or cellular host transformed with such molecule and a polypeptide showing interferon activity prepared by such host
SE8403929D0 (sv) Recombinant dna molecule, transformed microorganisms and process for producing penicillin v amidase

Legal Events

Date Code Title Description
PC1A Transfer granted

Owner name: BIOGEN, INC.

FD1A Patent lapsed

Effective date: 19991007